Global Gastroesophageal Reflux Disease Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Gastroesophageal Reflux Disease Therapeutics Market is presumed to reach the market size of nearly USD 12.45 BN by 2030 from USD 7.8 BN in 2022 with a CAGR of 6.02% under the study period 2023 - 2030.

Gastroesophageal reflux disease therapeutics device (GERD) provides an alternate method for treating heartburn. It is essentially a condition wherein the lower esophageal sphincter (LES) relaxes or fails to function effectively, allowing stomach liquids to reflux back into the oesophagus, thus, causing heartburn. Stress, hiatal hernia, abdominal obesity, and smoking are all risk factors for GERD. These devices are advantageous as they provide an option for minimally invasive surgery to address inherent anatomical deformities. They are slowly gaining ground with evolving supportive medical proofs for machines to carry out the treatment. However, their biggest disadvantage is that they still need to be clinically proven.

Market Dynamics:

Major factors such as the rising prevalence of gastrointestinal reflux diseases, changing lifestyles, and increasing awareness are expected to fuel the gastroesophageal reflux disease therapeutics market. Further, using these devices for minimally invasive procedures is steadily gaining traction with growing supportive clinical evidence. This will help perform procedures, such as transoral fundoplication, which prevent acid and non-acid contents' reflux. On the downside, the market may experience a decline due to the patent expiration of popular medications used to treat acid reflux diseases. Nonetheless, the gastroesophageal reflux disease therapeutics market is set to expand in the future years as heartburn prevalence increases globally.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gastroesophageal reflux disease therapeutics. The growth and trends of gastroesophageal reflux disease therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the gastroesophageal reflux disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Antacids
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Pro-Kinetic Agents

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Gastroesophageal Reflux Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gastroesophageal reflux disease therapeutics market include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., and Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR112110081

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG TYPE

6.1 Overview by Drug Type
6.2 Historical and Forecast Data
6.3 Analysis by Drug Type
6.4 Antacids Historic and Forecast Sales by Regions
6.5 H2 Receptor Blockers Historic and Forecast Sales by Regions
6.6 Proton Pump Inhibitors (PPIs) Historic and Forecast Sales by Regions
6.7 Pro-kinetic Agents Historic and Forecast Sales by Regions

7 . GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS COMPANIES

8.1. Gastroesophageal Reflux Disease Therapeutics Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. AstraZeneca PLC
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Eisai Co. Ltd.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GlaxoSmithKline PLC
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Takeda Pharmaceutical Co. Ltd.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Johnson & Johnson.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies